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Introduction
Miscarriage is a frequent complication in the first trimester which occurs in 10-15% of pregnancies. (1) In the last decade, misoprostol was introduced as treatment option for first trimester miscarriages next to expectant management and curettage. (2) (3) (4) (5) Misoprostol is effective in 50-85% of the women who have a miscarriage, while in the remaining women, ultrasound scanning during follow-up shows incomplete evacuation of the uterus.(4-8) Despite most women being relatively asymptomatic, this finding generally leads to additional curettage. Medical management for miscarriage was found to be cost-effective in comparison with curettage in several studies (9) (10) (11) (12) (13) , although this result was not confirmed by others. (14, 15) The MisoREST trial was a randomized controlled trial (RCT) comparing curettage and expectant management in women with incomplete evacuation of the uterus after misoprostol treatment for first trimester miscarriage. (16) In this trial, significantly more women had an empty uterus after curettage than after expectant management (96% versus 83%, RR 1.15, 95% CI 1.06-1.25). Considering the high prevalence of miscarriage and the high costs associated with curettage as compared to expectant management, it is important to evaluate whether the additional costs of curettage in case of an incomplete evacuation are justified by the additional clinical effects.
Methods

Study design
This economic evaluation was conducted alongside the MisoREST trial, which was a combination of a RCT and a prospective cohort study conducted in 27 Dutch hospitals. For further details, we refer to the publication of the MisoREST trial. (16) Outcomes Primary outcome was curation at follow-up 6 weeks after study entry; defined as sonographic finding of an empty uterus six weeks after study entry or an uneventful course. Quality of life was measured at baseline, 2 and 4 weeks of follow-up using the SF-36. (17) Health states based on the SF-36 were converted to utility scores using the SF-6D tariff developed by Brazier et al. (18) Quality-Adjusted LifeYears (QALYs) were calculated by multiplying the utility score belonging to a health state by the time spent in this state. Changes in utility scores between health states were estimated using linear interpolation.
Costs
Resource use was measured from a societal perspective. Women received a weekly questionnaire to report on health-related costs, and the Health and Labor questionnaire after 4 weeks to report on their absenteeism from work and/or other daily tasks, and on presenteeism. (19) Dutch guidelines on costing were used to estimate unit costs. When available Dutch standard costs were used to value healthcare utilization.(19) Medication use was valued using prices from a website (www.medicijnkosten.nl). Costs of absenteeism from paid work and presenteeism were calculated using Dutch mean sick leave costs. (19) All costs were expressed in 2014 euros and inflated when necessary using the costumer price index. A bottom-up cost price calculation was done to estimate costs of a curettage and hysteroscopy. This included salary costs of healthcare providers, costs of the operating room including overhead costs 122 and costs of materials needed. We retrieved unit costs estimates from the financial departments of a non-academic hospital and academic. Appendix 1 lists all prices used in this economic evaluation.
Analysis
Analyses were performed according to the intention to treat principle, using StataSE 12. Since the interaction term of group allocation and treatment preference between the randomized and nonrandomized women was not statistically significant (p>0.05) we combined these groups. Multivariate Imputation by Chained Equations (MICE) algorithm was used to impute missing cost and effect data. (20) An imputation model was created that contained variables that were related to missing data or the outcome measure, and variables that differed at baseline between the groups. Predictive mean matching was used to account for the skewed distribution of costs. Ten imputed data sets were created to reach a fraction of missing information of less than 5%, each of which was analyzed separately. The results of the 10 analyses were pooled using Rubin's rules. (21) Both a cost-effectiveness analysis, and a cost-utility were performed. Bivariate regression analysis was used to estimate cost and effect differences between the groups while accounting for potential correlation between costs and outcomes. (22) Incremental cost-effectiveness ratios (ICERs) were calculated by dividing the difference in total costs between the treatment groups by the difference in clinical effects. Non-parametric bootstrapping with 5, 000 replications was used to estimate statistical uncertainty. (23) The bootstrapped cost-effect pairs were plotted on a cost-effectiveness plane (CE plane) and used to estimate cost-effectiveness acceptability curves (CEA curves).
Sensitivity/scenario analyses
In the sensitivity analysis, we conducted the economic evaluation from a NHS (National Health Service) perspective indicating that only healthcare costs were taken into account. In a scenario analysis, we assumed that all women would have a curettage under conscious sedation in an outpatient clinic setting.
Details of ethics approval
The study was approved by the research ethics service committee of the Academic Medical Centre (project number 2011-373); research governance approvals were granted by participating hospitals and all patients gave informed consent.
Trial registration
Dutch Trial Register NTR3310, http://www.trialregister.nl
Results
Between June 2012 and July 2014, a total of 59 women were randomized (30 curettage and 29 expectant management), while 197 women were treated according to their own preference (65 curettage and 132 expectant management). Demographic characteristics are shown in table 1. Complete data was available on the primary outcome and no information on (re-)interventions or (re-)admissions was missing. Response to the SF-36 at baseline was 77%, and 74% at two and four weeks. Response to the Health and Labor, and to the healthcare utilization questionnaire was 77%.
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Gynecological interventions and complications
In the curettage group all women underwent curettage. A re-intervention was performed in 11/95 women. In the expectant management group an intervention was performed in 31/161 women. Adverse outcomes such as excessive bleeding or antibiotic treatment occurred in 7 women in the curettage (7.4%) and in 6 women who were treated expectantly (3.7%).
Costs
Healthcare costs in the curettage group were significantly higher than in the expectant management group (mean difference €1,157, 95% CI 955; 1,388). This difference was primarily caused by the costs of the surgical procedure in the curettage group. Differences in patient costs and lost productivity costs between the two treatment groups were not significant. (Table 2) 124 
Cost-effectiveness
Cost-effectiveness of the primary analysis, sensitivity and scenario analysis is summarized in Table 3 . The ICER for curation was €8,586 indicating that the extra costs per extra woman cured were €8,586 in the curettage group as compared to the expectant management group. The CEA curve (Figure 1 ) shows that at a willingness-to-pay of 18,200 €/cured woman extra the probability that curettage is cost-effective compared to expectant management is 95%. For QALYs, the ICER was -418,895 €/QALY indicating that €418,895 extra needs to be invested in the curettage group as compared to the expectant management group to lose 1 QALY.
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Sensitivity/ Scenario Analysis
In the analysis conducted from the NHS perspective the ICER indicated that €8781 needs to be invested per extra cured woman. (table 3) The CEA curve shows that at a ceiling ratio of 17,000 €/cured woman extra, the probability that curettage is cost-effective as compared with expectant management is 95% (data not shown). When assuming that all women would have curettage under conscious sedation, the additional costs for one extra woman cured were €3,601. table 3) At a willingness-to-pay of 8,000 €/extra woman cured the probability that curettage is cost-effective in comparison with expectant management is 95%. 
Discussion
Principle findings
Curettage resulted in significantly more women cured than expectant management, but was also significantly more expensive. The difference in costs mainly originated from the curettage procedure itself. The incremental cost of performing a curettage as compared to expectant management was €8,586 for one extra cured woman. The probability that curettage is cost-effective in comparison with expectant management was 95% at a willingness-to-pay of 18,200 €/ extra cured woman. Results from a NHS perspective were similar. Incremental costs for curettage under conscious sedation were just over €3,600.
Strengths and limitations
This study was performed alongside a combined RCT and patient preference trial with a pragmatic design in which a diverse group of hospitals participated resulting in high external validity. Costs data were collected prospectively from a societal perspective including not only healthcare, but also patient costs and lost productivity costs. A limitation of the study was that the response to the healthcare utilization and lost productivity questionnaires was 77%, which may have led to selection bias. We tried to overcome this by using multiple imputation which is currently considered the most appropriate technique to deal with missing data. (24, 25) A substantial part of the part of the included women were not randomized due to a strong treatment preference. Endometrial thickness (AP diameter of uterine cavity) differed at baseline between the two groups. Previous analysis however showed that endometrial thickness has no predictive value for treatment success.(16) Furthermore, there was no significant interaction group allocation and treatment preference. All health-related costs were collected up to four weeks from study entry. This time frame might have been too short since long term complications such as intra uterine adhesions and preterm birth in a following pregnancy (which will generate extra costs), cannot be assessed this early. (26, 27) Since all costs were estimates based on Dutch reference prices and health care practice, the impact of using country specific prices and assumptions should be considered before generalizing these results to other countries.
Comparison with other studies
To our knowledge this is the first economic evaluation comparing curettage versus expectant management in the treatment of an incomplete evacuation of the uterus after primary treatment with misoprostol. Several other cost-effectiveness studies have been conducted on the primary treatment of first trimester miscarriage. Graziosi et al showed curettage to be effective but more expensive than misoprostol, and concluded curettage not to be cost-effective in comparison with misoprostol as primary treatment for first trimester miscarriage.(9) Both Niinimäki et al. and Rausch et al. showed that the beneficial effects on costs with misoprostol or expectant management to be smaller, or to even disappear when curettage is performed in an outpatient setting while effects of the two treatments are not significantly different. (12, 14) In those studies, medical treatment was relatively more expensive, and curettage relatively less expensive especially when compared to the present study.
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Implications of the results
With the increasing use of misoprostol in first trimester miscarriages, the occurrence of an incomplete evacuation of the uterus becomes more frequent. In the MisoREST study, expectant management was effective in 5 out of every 6 women.(16) Our results show that decision makers should be willing to pay a relatively high price to be confident that curettage is cost-effective for these cases. Based on our findings, we feel that guidelines and protocols should recommend expectant management in these situations, while curettage should be reserved for specific cases. Research should establish whether there are factors that predict the probability of an empty uterus after expectant management enabling healthcare providers to offer tailored treatment to their patients.
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